Intermittent and Continuous ADT Offer Similar Survival
Intermittent and continuous androgen suppression is associated with similar overall survival in patients who have rising PSA after radiotherapy for prostate cancer (PCa), according to a study.
The study of 1,386 patients found that median overall survival was 8.8 years for the 690 patients randomly assigned to receive intermittent androgen deprivation therapy (ADT) and 9.1 years for the 696 patients randomly assigned to receive continuous ADT. The estimated seven-year cumulative rates of disease-related death were 18% and 15%, respectively, the researchers reported in the New England Journal of Medicine (2012;367:895-903). The differences between the groups were not statistically significant.
The study, led by Juanita M. Crook, MD, of the British Columbia Cancer Agency in Kelowna, British Columbia, enrolled patients who had a PSA level higher than 3 ng/mL more than one year after primary or salvage radiotherapy for localized PCa. The median follow-up was 6.9 years.
The investigators found that intermittent treatment provided potential benefits with respect to physical function, fatigue, hot flashes, libido, erectile function, and urinary problems.